Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

Buti M., Tsai N., Petersen J., Flisiak R., GÜREL S., Krastev Z., ...Daha Fazla

DIGESTIVE DISEASES AND SCIENCES, cilt.60, sa.5, ss.1457-1464, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 5
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s10620-014-3486-7
  • Dergi Adı: DIGESTIVE DISEASES AND SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1457-1464
  • Anahtar Kelimeler: Antiviral agent, Cirrhosis, Hepatitis B e antigen, Liver disease, LONG-TERM EFFICACY, ADEFOVIR DIPIVOXIL, ENTECAVIR TREATMENT, NAIVE PATIENTS, LAMIVUDINE, CIRRHOSIS, RISK
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background Long-term tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB) is associated with sustained viral suppression and regression of fibrosis and cirrhosis at year 5 (240 weeks) and no TDF resistance through 6 years (288 weeks).